BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol. 2013;71:257-264. [PMID: 23100174 DOI: 10.1007/s00280-012-2004-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Rosati G. Combination therapy for older men with colorectal cancer: are two drugs better than one? Expert Rev Anticancer Ther 2013;13:1013-6. [PMID: 24053200 DOI: 10.1586/14737140.2013.826984] [Reference Citation Analysis]
2 Petrelli F, Coinu A, Ghilardi M, Cabiddu M, Zaniboni A, Barni S. Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials. Am J Clin Oncol 2015;38:227-33. [PMID: 25806713 DOI: 10.1097/COC.0b013e3182a2d7b8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
3 Moriwaki T, Sakai Y, Ishida H, Yamamoto Y, Endo S, Kuramochi H, Sato M, Hatachi Y, Bando Y, Maeba T, Ikezawa K, Shimada M, Amagai K, Morimoto M, Kobayashi K, Tsuji A, Nishina T, Hyodo I. Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER). Int J Clin Oncol 2019;24:1214-22. [PMID: 31089842 DOI: 10.1007/s10147-019-01465-3] [Reference Citation Analysis]
4 Grapsa D, Syrigos K, Saif MW. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther 2015;15:1267-81. [PMID: 26506906 DOI: 10.1586/14737140.2015.1102063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
5 Rosati G, Cordio S, Reggiardo G, Aprile G, Butera A, Avallone A, Tucci A, Novello G, Blanco G, Caputo G, Bilancia D, Bordonaro R. Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials. Cancers (Basel) 2019;11:E578. [PMID: 31022922 DOI: 10.3390/cancers11040578] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Losa F, Bosch C, Escudero P, Casado E, Jorge M, Bohn U, Pérez-Carrión R, Carmona A, Custodio AB, Maurel J. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One 2015;10:e0116527. [PMID: 25602286 DOI: 10.1371/journal.pone.0116527] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
7 Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Vera R, Serra O, Casado E, Jorge M, Escudero P, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Martínez-Marín V, Maurel J. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br J Cancer 2014;111:241-8. [PMID: 24946000 DOI: 10.1038/bjc.2014.346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
8 Hanna RM, Lopez E, Wilson J, Barathan S, Cohen AH. Minimal change disease onset observed after bevacizumab administration. Clin Kidney J. 2016;9:239-244. [PMID: 26985375 DOI: 10.1093/ckj/sfv139] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
9 Benavides M, Berciano-guerrero M. Elderly patients with metastatic colorectal cancer: overall issues and first-line chemotherapy options. Colorectal Cancer 2013;2:559-71. [DOI: 10.2217/crc.13.69] [Reference Citation Analysis]
10 Aprile G, Fontanella C, Lutrino ES, Ferrari L, Casagrande M, Cardellino GG, Rosati G, Fasola G. Angiogenic inhibitors for older patients with advanced colorectal cancer: Does the age hold the stage? World J Gastroenterol 2013; 19(14): 2131-2140 [PMID: 23847406 DOI: 10.3748/wjg.v19.i14.2131] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
11 Tapia Rico G, Townsend AR, Broadbridge V, Price TJ. Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Drugs Aging 2017;34:173-89. [PMID: 28197947 DOI: 10.1007/s40266-017-0439-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
12 Hanna RM, Lopez EA, Hasnain H, Selamet U, Wilson J, Youssef PN, Akladeous N, Bunnapradist S, Gorin MB. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J 2019;12:92-100. [PMID: 30746134 DOI: 10.1093/ckj/sfy060] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
13 Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int 2019;96:572-80. [PMID: 31229276 DOI: 10.1016/j.kint.2019.02.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
14 Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288 [PMID: 26109816 DOI: 10.3748/wjg.v21.i23.7281] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
15 Mabuchi S, Yamamoto M, Murata H, Yokoe T, Hamanishi J, Terai Y, Imatake H, Mabuchi Y, Mori T, Kitada F, Hashiguchi Y, Takahashi A, Fujiwara S, Naoi H, Matsubara S. Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan. Int J Clin Oncol 2021;26:598-605. [PMID: 33185777 DOI: 10.1007/s10147-020-01826-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]